Business
Sun BioPharma, Inc. Provides Business Update and Reports Q2 2020 Financial Results
Sun BioPharma, Inc. Provides Business Update and Reports Q2 2020 Financial Results.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\n MINNEAPOLIS, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended June 30, 2020. The second quarter of 2020 was marked by meaningful corporate, financial and clinical progress. Highlights New CEO appointed on July 15, 2020Enrollment in clinical trial of SBP-101 has resumed, after temporary, Covid-19 related pauseFast Track designation received for SBP-101Additional funds raised through sale of equity securities CEO AppointmentIn July, the company appointed of Jennifer K. Simpson, PhD, MSN, CRNP as President and Chief Executive Officer and as a member of the Board of Directors. Dr. Simpson brings more than two decades of public company executive and fundraising experience in oncology drug development and commercialization to the company. Sun BioPharma co-founder Michael T. Cullen, MD, MBA, has continued to serve as Executive Chairman of our Board of Directors. “I’m excited that we were able to resume enrollment in our clinical trial of SBP-101 in order to keep advancing this program for the patients who need it most,” said Jennifer K. Simpson, PhD, MSN, CRNP President & Chief Executive Officer of Sun BioPharma. “The company is well positioned to maximize the opportunity for value of this product candidate for patients, caregivers and investors, and we look forward to completing the design of our Phase 2 development program shortly.\" Enrollment Resumed in Ongoing Clinical Trial of SBP-101In June, Sun BioPharma authorized clinical trial sites to resume enrollment in the expansion cohort of its Phase 1a/b clinical trial of SNBP-101. Enrollment in many clinical trials across the industry had been temporarily paused earlier this year to enable hospitals to prioritize the treatment of patients with COVID-19. This trial, a Phase 1a/1b study of the combination of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), is being conducted at 6 sites in the United States and Australia. FDA Fast Track Designation Received for SBP-101During the second quarter, the company received Fast Track Designation from...